# GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer

> **NCT04206254** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Cure&Sure Biotech Co., LTD** · enrollment: 80 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** gp96

## Key facts

- **NCT ID:** NCT04206254
- **Lead sponsor:** Cure&Sure Biotech Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-19
- **Primary completion:** 2022-08-05
- **Final completion:** 2023-08-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04206254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04206254, "GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04206254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*